๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 15 Shanghai 14 Wuhan 11 Nanjing 7 Jinan 6
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing15 Shanghai14 Wuhan11 Nanjing7 Jinan6
All 23 locations
Target enrolment
to

Trials with a site in Shanghai

14 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
NCT07817615Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
60
Shanghai
2026-09
Recruiting
A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.
NCT07547995Uveitis
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
74
Shanghai
2026-06-29
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants
NCT07476586Healthy Volunteers
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
44
Shanghai
2026-04-20
Recruiting
A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.
NCT07366866Autoimmune Disease
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
48
Shanghai
2026-03-16
Recruiting
A Study๏ผˆPhase I๏ผ‰of GS3-007a Dry Suspension in Healthy Chinese Adults
NCT07473570Healthy Adults
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
32
Shanghai
2026-01-07
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
NCT07252414Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
180
Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Shanghai, Taiyuan, Hangzhou
2025-12-20
Not yet open
A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women
NCT07302035Bacterial Vaginosis
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
30
Shanghai
2025-12
Recruiting
Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
NCT07040930Rheumatoid Arthritis
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
30
Shanghai
2025-08-01
Recruiting
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
NCT06908434Solid Tumors Harboring a TP53 Y220C Mutation
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
82
Shanghai
2025-06-10
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
NCT06772415Advanced Solid Tumor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
163
Beijing, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Tianjin
2025-01-08
Recruiting
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
NCT06569758Safety, Tolerability, GenSci098, Thyroid Eye Disease (TED)
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
76
Shanghai
2024-09-24
Active, closed
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
NCT06449027Breast Cancer Subjects
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
211
Shanghai
2024-08-21
Recruiting
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
NCT05925452Active Systemic Juvenile Idiopathic Arthritis
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
290
Beijing, Chongqing, Changsha, Nanjing, Suzhou, Shanghai, Xiโ€™an, Chengdu
2023-12-01
Active, closed
Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature
NCT02375620Short Stature Children Born Small for Gestational Age (SGA)
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
96
Beijing, Wuhan, Changsha, Wuxi, Nanchang, Changchun, Shanghai, Taiyuan
2015-04-23
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

10 of the 14 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 14 studies
PhaseStudiesRecruitingShare
Phase 110871.4%
Phase 22114.3%
Not applicable117.1%
Phase 3107.1%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Changchun GeneScience Pharmaceutical Co., Ltd.1410
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.